Top drugs and pharmaceutical companies of 2018 by revenues

The drug pricing debate continued to dominate news headlines in 2018, and many companies were in the news for lowering drug prices to make treatments more affordable.

Despite that, most major pharmaceutical companies saw their sales grow in 2018.

Pfizer, Novartis, Roche, J&J and Merck posted the highest pharmaceutical sales last year. While the top order of Big Pharma effectively remained unchanged, companies like Sanofi and Gilead saw lackluster performance due to drop in sales.

This week, PharmaCompass brings you a compilation of the top pharmaceutical companies of 2018 by revenues.

Pfizer topped the charts with revenues of US$ 53.65 billion in 2018, as compared to US$ 52.55 billion posted the previous year. Last year, Pfizer had announced that its chief operating officer Albert Bourla would succeed Ian Read as its CEO from January 1, 2019. Ian Read is now serving as Pfizer’s executive chairman.

Since Bourla was part of Ian Read’s executive leadership team, Pfizer’s strategy to grow based on its own internal pipeline and new launches is not expected to change significantly. However, the focus on digital will certainly increase as almost immediately after he took over, Pfizer announced a revamp of its executive team with the appointment of a chief digital officer.

Novartis followed Pfizer with the second largest revenues in the pharmaceutical industry at US$ 51.90 billion, up from US$ 49.11 billion the previous year. Novartis’ Alcon division, which got spun off recently, had US$ 7.15 billion in 2018 sales. Its generic arm Sandoz, which had its oral solid dosage division in the United States sold off last year and is expected to undergo further restructuring over the next year or more, contributed US$ 9.86 billion to Novartis’ topline.

Under a new CEO, Vas Narasimhan, the company was also busy dealmaking — it enhanced its investment into gene therapy by buying Avexis for US$ 8.7 billion in April. It also bought Endocyte for US$ 2.1 billion to add another product to its radioligand portfolio.

Check the interactive table here

At number three was Swiss drug giant Roche with total revenues of US$ 60.09 billion. Of this, US$ 46.98 billion accrued from its pharmaceutical operations while the remaining US$ 13 billion came from its diagnostics division. These numbers include US$ 2.67 billion, which Roche reported as income from royalties and other operating incomes. The overall group sales were up 7 percent in Swiss Francs while core operating profit grew 9 percent.

Last year also saw J&J report worldwide sales of US$ 81.58 billion, an increase of 6.7 percent as compared to its 2017 sales. J&J’s pharmaceutical division generated US$ 40.73 billion and its medical devices and consumer health divisions brought in US$ 26.99 billion and US$ 13.85 billion respectively. Since J&J’s consumer health division sells analgesics, digestive health along with beauty and oral care products, the unit was excluded from our compilation while assessing the total pharmaceutical revenues.

Merck’s worldwide sales in 2018 were US$ 42.29 billion, an increase of 5 percent over the previous year. Merck sales could have been marginally higher, but it lost out on revenues due to a cyber-attack that took place in June 2017. The attack led to a US$ 150 million drop in revenue in 2018, as opposed to a US$ 260 million drop in revenues in 2017. Merck’s pharmaceutical sales stood at US$ 37.69 billion in 2018 — an increase of almost US$ 2.3 billion over the previous year. Its animal health division brought in US$ 4.21 billion in sales. The firm’s key oncology drug — Keytruda — reported sales increase of US$ 3.36 billion.

Continue reading